Advertisement

Topics

Sarcoma: Does histotype-tailored neoadjuvant therapy improve outcomes?

07:18 EDT 9 Aug 2017 | Nature Publishing

Patients with metastatic soft-tissue sarcoma can benefit from systemic therapy, but the best drug combinations for the different disease subtypes remain to be established. Recently, great emphasis has been placed on histology-based chemotherapy regimens. Herein, we discuss the results of a recently published study demonstrating that some of these regimens are not superior to standard-of-care chemotherapy in the neoadjuvant setting.

Original Article: Sarcoma: Does histotype-tailored neoadjuvant therapy improve outcomes?

NEXT ARTICLE

More From BioPortfolio on "Sarcoma: Does histotype-tailored neoadjuvant therapy improve outcomes?"

Quick Search
Advertisement
 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...